In a significant move to revolutionize drug development, Lisata Therapeutics (Nasdaq: LSTA) and GATC Health Corp have announced their strategic collaboration, combining advanced artificial intelligence with traditional pharmaceutical expertise. The partnership will leverage GATC's proprietary AI-powered Multiomics Advanced Technology™ (MAT) platform to streamline and optimize drug development processes.
AI-Driven Analysis of Certepetide
The initial phase of the collaboration focuses on Lisata's investigational drug certepetide, currently being developed for metastatic pancreatic ductal adenocarcinoma (mPDAC). GATC's MAT AI platform will conduct comprehensive analyses to predict safety, efficacy, and potential clinical outcomes across multiple indications. This analysis aims to optimize the ongoing Phase 3 development while identifying additional promising therapeutic applications.
"By combining our expertise with GATC and their cutting-edge AI technology, we are ensuring that Lisata's and GATC's development programs have the highest probability of success," stated David J. Mazzo, Ph.D., President and CEO of Lisata Therapeutics. "This allows us to conduct the most time- and capital-efficient studies to accelerate products to market."
Transforming Traditional Drug Development
The collaboration addresses a critical challenge in pharmaceutical development, where traditionally only 1 in 10,000 potential drugs reaches the market, often requiring over a decade and billions in investment. GATC's MAT AI platform simulates billions of complex biological interactions, potentially reducing development timelines and costs while increasing success rates.
Jayson Uffens, Chief Technology Officer at GATC, explained, "GATC's validated technology inverts predicted clinical trial failures and provides an unbiased analysis of investigational new drugs. This enables a derisked and optimized development roadmap that can include additional indications and new intellectual property."
Expanding Therapeutic Possibilities
The partnership's scope extends beyond certepetide analysis. Future phases will identify potential combination therapies across various indications, including areas outside oncology. Additionally, Lisata will serve as an operational partner for GATC's drug development candidates, which currently target conditions including addiction, PTSD, diabetes, obesity, glioblastoma, and cognitive decline.
Strategic Impact on Drug Development
This collaboration represents a significant shift in drug development strategy, combining Lisata's clinical expertise with GATC's advanced AI capabilities. The partnership has gained additional credibility through GATC's selection as the exclusive AI partner for Lloyd's of London's syndicate, Medical & Commercial International, supporting the first insurance-backed financial program for clinical trials.
The companies expect this AI-driven approach to significantly reduce development risks while enabling more focused studies and optimized capital management. This strategic alliance positions both companies at the forefront of innovative drug development, potentially transforming how new therapeutics are brought to market.
